News & Events

Press Releases

June 6 2008

vasopharm closes € 4.5 million Series D Investment

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announced positive results of a phase Ib study with its antipterin VAS203 which is a new allosteric NOS modulator. The placebo-controlled, double blind study was performed in order to investigate safety, tolerability and pharmacokinetics of VAS203 after repetitive dosing. The drug was given via a daily infusion up to three consecutive days and was found to be safe and well tolerated. The same treatment regimen is considered for the upcoming clinical phase II trial.

Read on Download PDF
December 28 2006

First human study with vasopharm's trauma compound VAS203

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, announced today that the company has received a positive ethics vote from the Landesärztekammer Baden-Württemberg, Stuttgart, Germany and the necessary approval from the Federal Institute for Drugs and Medical Devices, Germany (BfArM) for the first study in humans of VAS203.

Read on Download PDF
September 5 2006

European Commission Grants Orphan Medicinal Product Designation for vasopharm's drug candidate VAS203

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, announced today that the European Commission has granted orphan medicinal product status for its drug candidate VAS203 for the treatment of traumatic brain injury. This designation is based on a recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA). VAS203, a NO Synthase modulator, is developed exclusively for the acute indication of closed head injury.

Read on Download PDF